Floatz logo

Zonisamide

Focal Epilepsy

Azurity PharmaceuticalsSmall moleculePhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Focal Epilepsy cohort.

Asset / SponsorPhaseRating
Eslicarbazepine Acetate
Sumitomo Pharma America, Inc.
Phase 4A
Pregabalin
Yung Shin Pharm. Ind. Co., Ltd.
Phase 4A
Topiramate
Mario Negri Institute for Pharmacological Research
Phase 4A
Oxcarbazepine
Mario Negri Institute for Pharmacological Research
Phase 4A
Lacosamide
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase 4A

View all 50 →

Same molecule, other indications

Zonisamide is also rated in:

epilepsyActive
BB
Indicative · Phase 4
69 / 100
View asset →
migraine disorderActive
B
Indicative · Phase 4
63 / 100
View asset →
epilepsy with generalized tonic-clonic seizuresActive
B
Indicative · Phase 4
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →